<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04278144</url>
  </required_header>
  <id_info>
    <org_study_id>BBI-20201001</org_study_id>
    <nct_id>NCT04278144</nct_id>
  </id_info>
  <brief_title>A First-in-human Study Using BDC-1001 in Advanced and HER2-Expressing Solid Tumors</brief_title>
  <official_title>Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced HER2-Expressing Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bolt Biotherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bolt Biotherapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A first-in-human study using BDC-1001 in HER2 expressing advanced malignancies
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study has four parts. Part 1 is a dose escalation of BDC-1001 as a single agent to
      determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), or maximum
      protocol dose (MPD) recommended for Part 3. In Part 3, the selected dose will be administered
      as monotherapy to patients with selected advanced malignancies. Part 2 is a dose escalation
      of BDC-1001 in combination with pembrolizumab to determine the maximum tolerated dose (MTD),
      recommended Phase 2 dose (RP2D), or maximum protocol dose (MPD) recommended for Part 4. In
      Part 4, the selected dose will be administered in combination with pembrolizumab to patients
      with selected advanced malignancies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multiple ascending dose and dose-expansion of BDC-1001 administered as a single agent or in combination with pembrolizumab.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation period only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and nature of dose-limiting toxicities (DLTs)</measure>
    <time_frame>21 days</time_frame>
    <description>Escalation period only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of potential-immune related toxicities</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation period only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerable dose (MTD) or a tolerated dose below MTD</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation period only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (ORR) of confirmed complete or partial responses (CR, PR)</measure>
    <time_frame>2 years</time_frame>
    <description>Expansion period only</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK (Cmax) of BDC-1001 as monotherapy and in combination with pembrolizumab</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation and expansion periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK (Cmin) of BDC-1001 as monotherapy and in combination with pembrolizumab</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation and expansion periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK (AUC) of BDC-1001 as monotherapy and in combination with pembrolizumab</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation and expansion periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK (CL) of BDC-1001 as monotherapy and in combination with pembrolizumab</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation and expansion periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK (Vz) of BDC-1001 as monotherapy and in combination with pembrolizumab</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation and expansion periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK (t1/2) of BDC-1001 as monotherapy and in combination with pembrolizumab</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation and expansion periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) of confirmed complete or partial responses (CR, PR)</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation period only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation and expansion periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) of confirmed responses lasting 4 or more weeks</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation and expansion periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation and expansion periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation period only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-BDC-1001 antibodies and neutralizing antibodies to BDC-1001 or pembrolizumab</measure>
    <time_frame>2 years</time_frame>
    <description>Escalation and expansion periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>2 years</time_frame>
    <description>Expansion period only</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Neoplasm, Metastatic</condition>
  <condition>Neoplasm, Breast</condition>
  <condition>Neoplasm, Gastric</condition>
  <arm_group>
    <arm_group_label>Single agent BDC-1001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses followed by expansion targeting breast and non-breast HER2 advanced malignancies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination BDC-1001 plus pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses followed by expansion targeting breast and non-breast HER2 advanced malignancies</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BDC-1001</intervention_name>
    <description>Immune stimulating antibody conjugate (ISAC), consisting of an anti-HER2 monoclonal antibody conjugated to a TLR 7/8 dual agonist</description>
    <arm_group_label>Combination BDC-1001 plus pembrolizumab</arm_group_label>
    <arm_group_label>Single agent BDC-1001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Programmed death receptor-1 (PD 1)-blocking antibody</description>
    <arm_group_label>Combination BDC-1001 plus pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Patient must have an advanced solid tumor with documented HER2-protein expression or
             gene amplification for which approved therapies have been exhausted or are not
             clinically indicated.

          -  Measurable disease as determined by RECIST v.1.1.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Tumor tissue (archival or collected prior to the study start) available for
             exploratory biomarker evaluation.

        Key Exclusion Criteria:

          -  History of severe hypersensitivity to any ingredient of the study drug(s), including
             trastuzumab or other monoclonal antibody.

          -  Previous treatment with a TLR 7, TLR 8 or a TLR 7/8 agonist.

          -  For the combination portion of the study, previous treatment with an anti-PD1 or anti-
             PD-L1 therapy.

          -  Impaired cardiac function or history of clinically significant cardiac disease

          -  Human Immunodeficiency virus (HIV) infection, active hepatitis B infection, or
             hepatitis C infection.

          -  Untreated central nervous system (CNS), epidural tumor or metastasis, or brain
             metastasis.

        Other protocol defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edith A Perez, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bolt Biotherapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bolt Biotherapeutics</last_name>
    <phone>1-650-665-9295</phone>
    <email>info@boltbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bolt Investigative Site</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bolt Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bolt Investigative Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bolt Investigative Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bolt Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bolt Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bolt Investigative Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

